Zyn exposes you to fewer cancer-causing chemicals than chewing tobacco, but it is not safe. Because Zyn contains no actual tobacco leaf, it avoids many of the carcinogens found in traditional chew. However, both products deliver nicotine through your mouth tissue, and nicotine itself carries real cardiovascular risks regardless of how it enters your body.
What Zyn Leaves Out
Chewing tobacco contains tobacco-specific nitrosamines, a group of compounds strongly linked to cancers of the mouth, esophagus, and pancreas. Zyn does not contain tobacco leaf at all. Instead, the pouches are filled with microcrystalline cellulose, plant fibers, maltitol, sweeteners, and nicotine salts. The FDA found that Zyn products contain “substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products such as moist snuff and snus,” which is why it authorized 20 Zyn products for legal marketing in 2024.
That authorization came with a clear caveat: it does not mean Zyn is safe, it is not “FDA approved” in the way a medication would be, and the company is not allowed to market Zyn as a reduced-risk product. Lower exposure to certain toxicants is not the same as lower disease risk, and long-term health data on nicotine pouches simply doesn’t exist yet.
How Nicotine Affects Your Heart and Blood Vessels
This is where the “better than chewing tobacco” framing gets complicated. Nicotine, no matter how you consume it, activates your sympathetic nervous system. It triggers the release of stress hormones like adrenaline and norepinephrine, which raise your heart rate, constrict blood vessels, and increase blood pressure. A 2025 review in the European Heart Journal was blunt: nicotine “accelerates atherosclerosis, even in non-combusted forms.”
Over time, repeated nicotine exposure promotes hypertension, irregular heart rhythms, and structural changes to the heart. It also damages the inner lining of blood vessels, a process called endothelial dysfunction. This damage has been documented not just in smokers but specifically in users of nicotine pouches. The review noted that oral nicotine products “still cause endothelial dysfunction, elevate sympathetic tone, likely impair autonomic regulation and increase blood pressure,” even though they eliminate inhaled toxicants.
Research from Sweden on snus, a closely related oral nicotine product, found higher cardiovascular and all-cause mortality among users, particularly those who had already experienced a heart attack or stroke. U.S. data from large population studies confirmed higher rates of hypertension and peripheral artery disease among smokeless nicotine users. These findings apply to nicotine delivered through any oral route, Zyn included.
Nicotine Delivery and Addiction
Both Zyn and chewing tobacco deliver nicotine through the tissue lining your mouth, and your body absorbs and processes the nicotine in essentially the same way. You place a Zyn pouch between your upper lip and gum for 15 to 45 minutes. Nicotine reaches your brain within about 10 seconds of entering your bloodstream. Some evidence suggests nicotine may enter your system faster from a pouch than from traditional chew, though this hasn’t been fully studied.
Zyn pouches come in varying strengths, and some contain nicotine concentrations higher than what you’d get from a cigarette. That matters because higher nicotine doses can deepen physical dependence. The CDC has not approved nicotine pouches as a cessation tool, and there is no solid evidence that switching from chewing tobacco to Zyn helps people quit nicotine altogether. For many users, the switch simply maintains the same addiction in a different package.
Cancer Risk: A Real but Incomplete Picture
The strongest argument for Zyn over chewing tobacco is cancer risk. Traditional chew contains at least 28 known carcinogens. Zyn, by removing tobacco leaf entirely, eliminates or drastically reduces exposure to most of them. If oral cancer and other tobacco-related cancers are your primary concern, that difference is meaningful.
But “lower” is not “zero.” The FDA’s review of Zyn focused on a limited set of harmful constituents, and researchers at UCSF have pointed out that reduced levels of certain chemicals on a regulatory checklist do not prove reduced disease risk in actual users. The nonclinical data submitted by Zyn’s manufacturer focused mainly on whether the product causes DNA damage, leaving broader health effects less well understood.
What This Means in Practice
If you currently use chewing tobacco and are weighing a switch to Zyn, the trade-offs look like this: you would substantially reduce your exposure to cancer-causing chemicals found in tobacco leaf. You would not reduce your exposure to nicotine or its effects on your cardiovascular system. You would remain addicted, potentially at a similar or even higher level of nicotine dependence depending on the pouch strength you choose.
Zyn is not a clean product that happens to contain nicotine. It is a nicotine delivery system, and nicotine itself damages blood vessels, raises blood pressure, stiffens arteries, and stresses the heart with every use. For someone choosing between Zyn and chewing tobacco with no intention of quitting nicotine entirely, Zyn likely presents a lower cancer risk. For someone trying to protect their overall health, neither product is a good option.